COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) major shareholder George Jay Goldsmith sold 23,881 shares of the firm's stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $8.53, for a total transaction of $203,704.93. Following the completion of the transaction, the insider now directly owns 3,986,523 shares in the company, valued at approximately $34,005,041.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
George Jay Goldsmith also recently made the following trade(s):
- On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.96, for a total transaction of $230,720.00.
- On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The shares were sold at an average price of $10.58, for a total value of $166,529.20.
- On Monday, January 22nd, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The shares were sold at an average price of $8.35, for a total value of $215,012.50.
- On Friday, January 19th, George Jay Goldsmith sold 20,205 shares of COMPASS Pathways stock. The shares were sold at an average price of $7.99, for a total value of $161,437.95.
COMPASS Pathways Price Performance
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
NASDAQ CMPS opened at $8.42 on Friday. COMPASS Pathways plc has a 12 month low of $5.01 and a 12 month high of $12.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.33 and a quick ratio of 13.33. The firm has a market capitalization of $521.53 million, a PE ratio of -3.52 and a beta of 2.48. The company's 50 day simple moving average is $9.98 and its 200 day simple moving average is $8.34.
COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). As a group, equities research analysts forecast that COMPASS Pathways plc will post -2.4 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms have recently weighed in on CMPS. Morgan Stanley began coverage on COMPASS Pathways in a report on Monday, April 1st. They set an "overweight" rating and a $30.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a report on Thursday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $120.00 price target on shares of COMPASS Pathways in a report on Friday, March 1st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, COMPASS Pathways presently has a consensus rating of "Buy" and an average price target of $47.40.
Get Our Latest Stock Analysis on CMPS
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC acquired a new position in COMPASS Pathways in the fourth quarter worth approximately $33,000. UBS Group AG grew its position in COMPASS Pathways by 249.1% in the fourth quarter. UBS Group AG now owns 4,291 shares of the company's stock worth $34,000 after buying an additional 3,062 shares during the last quarter. Quantbot Technologies LP grew its position in COMPASS Pathways by 156.8% in the first quarter. Quantbot Technologies LP now owns 3,338 shares of the company's stock worth $43,000 after buying an additional 2,038 shares during the last quarter. Advisor Group Holdings Inc. grew its position in COMPASS Pathways by 129.7% in the fourth quarter. Advisor Group Holdings Inc. now owns 5,406 shares of the company's stock worth $43,000 after buying an additional 3,052 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in COMPASS Pathways by 229.6% in the third quarter. Tower Research Capital LLC TRC now owns 7,847 shares of the company's stock worth $58,000 after buying an additional 5,466 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company's stock.
About COMPASS Pathways
(
Get Free Report)
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
